CIR and 95% CI stratified by post-transplantation HCMV pp65-antigenemia and disease genetic risk category. (A) CIR by post-transplantation pp65-antigenemia of patients with an intermediate genetic risk (P < .03). (B) CIR by post-transplantation pp65-antigenemia of patients with an adverse genetic risk (P < .0001). (C) CIR by post-transplantation HCMV antigenemia of patients with a favorable genetic risk (not significant). Tick marks indicate patients surviving free of relapse or competing events.